{"transactions":[{"id":873683,"issuer":{"id":1553,"kind":"organization","name":"Generate Biomedicines, Inc.","symbol":"GENB"},"owners":[{"id":63890,"kind":"person","name":"Simonian Nancy A","position":1,"cik":"0001359574","reported_name":"Simonian Nancy A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-02T17:55:47.000Z","date":"2026-02-26","kind":"grant","planned":false,"acquired":true,"shares":29561,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest in full on February 19, 2027, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":29561,"derivative":{"exercise_price":16,"expiration_date":"2036-02-25","underlying":"Common Stock","underlying_shares":29561},"source":{"system":"sec-edgar","filing":"0001193125-26-085903","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1359574/000119312526085903/ownership.xml","form_type":"4"}},{"id":1342639,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":63890,"kind":"person","name":"Simonian Nancy A","position":1,"cik":"0001359574","reported_name":"Simonian Nancy A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-12-04T17:00:05.000Z","date":"2024-12-02","kind":"sale","planned":false,"acquired":false,"shares":37070,"price":0.2702,"value":10016.314,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.2680 to $0.2726, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."}],"balance_after":4000,"source":{"system":"sec-edgar","filing":"0000950170-24-133338","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1359574/000095017024133338/ownership.xml","form_type":"4"}},{"id":1349039,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":63890,"kind":"person","name":"Simonian Nancy A","position":1,"cik":"0001359574","reported_name":"Simonian Nancy A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-27T17:00:04.000Z","date":"2024-11-25","kind":"sale","planned":false,"acquired":false,"shares":134713,"price":0.2653,"value":35739.3589,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.2604 to $0.2723, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."}],"balance_after":41070,"source":{"system":"sec-edgar","filing":"0000950170-24-131591","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1359574/000095017024131591/ownership.xml","form_type":"4"}},{"id":1376972,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":63890,"kind":"person","name":"Simonian Nancy A","position":1,"cik":"0001359574","reported_name":"Simonian Nancy A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2024-11-04T17:01:59.000Z","date":"2024-10-31","kind":"exercise","planned":false,"acquired":false,"shares":40125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Represents a restricted stock unit award granted on October 6, 2022. These restricted stock units vested as to one half (50%) of the shares on October 31, 2023, and as to one half (50%) of the shares on October 31, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Represents a restricted stock unit award granted on October 6, 2022. These restricted stock units vested as to one half (50%) of the shares on October 31, 2023, and as to one half (50%) of the shares on October 31, 2024."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":40125},"source":{"system":"sec-edgar","filing":"0000950170-24-120874","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1359574/000095017024120874/ownership.xml","form_type":"4"}},{"id":1376971,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":63890,"kind":"person","name":"Simonian Nancy A","position":1,"cik":"0001359574","reported_name":"Simonian Nancy A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-04T17:01:59.000Z","date":"2024-10-31","kind":"exercise","planned":false,"acquired":true,"shares":40125,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock received upon vesting of a restricted stock unit award."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of common stock received upon vesting of a restricted stock unit award."}],"balance_after":175783,"source":{"system":"sec-edgar","filing":"0000950170-24-120874","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1359574/000095017024120874/ownership.xml","form_type":"4"}},{"id":1486318,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":63890,"kind":"person","name":"Simonian Nancy A","position":1,"cik":"0001359574","reported_name":"Simonian Nancy A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-07T16:30:17.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the date of grant, with the remainder vesting in equal monthly installments of 8.33% of the shares underlying the award until the first anniversary of the date of grant, subject to the reporting person's continued service as a director through each applicable vesting date."}],"balance_after":6000,"derivative":{"exercise_price":5.3,"expiration_date":"2034-06-04","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0000950170-24-070706","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1359574/000095017024070706/ownership.xml","form_type":"4"}},{"id":1486317,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":63890,"kind":"person","name":"Simonian Nancy A","position":1,"cik":"0001359574","reported_name":"Simonian Nancy A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-07T16:30:17.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":135658,"source":{"system":"sec-edgar","filing":"0000950170-24-070706","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1359574/000095017024070706/ownership.xml","form_type":"4"}},{"id":1552901,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":63890,"kind":"person","name":"Simonian Nancy A","position":1,"cik":"0001359574","reported_name":"Simonian Nancy A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2024-04-02T16:59:57.000Z","date":"2024-03-31","kind":"exercise","planned":false,"acquired":false,"shares":39566,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Represents a restricted stock unit award granted on February 16, 2023. These restricted stock units vest in three equal annual installments commencing on March 31, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Represents a restricted stock unit award granted on February 16, 2023. These restricted stock units vest in three equal annual installments commencing on March 31, 2024."}],"balance_after":79134,"derivative":{"underlying":"Common Stock","underlying_shares":39566},"source":{"system":"sec-edgar","filing":"0000950170-24-040308","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1359574/000095017024040308/ownership.xml","form_type":"4"}},{"id":1552900,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":63890,"kind":"person","name":"Simonian Nancy A","position":1,"cik":"0001359574","reported_name":"Simonian Nancy A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2024-04-02T16:59:57.000Z","date":"2024-03-31","kind":"exercise","planned":false,"acquired":false,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Represents a restricted stock unit award granted on February 15, 2022. These restricted stock units vest in four equal annual installments commencing on March 31, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Represents a restricted stock unit award granted on February 15, 2022. These restricted stock units vest in four equal annual installments commencing on March 31, 2023."}],"balance_after":12000,"derivative":{"underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0000950170-24-040308","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1359574/000095017024040308/ownership.xml","form_type":"4"}},{"id":1552899,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":63890,"kind":"person","name":"Simonian Nancy A","position":1,"cik":"0001359574","reported_name":"Simonian Nancy A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-02T16:59:57.000Z","date":"2024-04-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":14052,"price":5.12,"value":71946.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares used to cover tax withholding upon the release of restricted stock units."}],"balance_after":131658,"source":{"system":"sec-edgar","filing":"0000950170-24-040308","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1359574/000095017024040308/ownership.xml","form_type":"4"}},{"id":1552898,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":63890,"kind":"person","name":"Simonian Nancy A","position":1,"cik":"0001359574","reported_name":"Simonian Nancy A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-02T16:59:57.000Z","date":"2024-03-31","kind":"exercise","planned":false,"acquired":true,"shares":39566,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock received upon vesting of a restricted stock unit award."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of common stock received upon vesting of a restricted stock unit award."}],"balance_after":145710,"source":{"system":"sec-edgar","filing":"0000950170-24-040308","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1359574/000095017024040308/ownership.xml","form_type":"4"}},{"id":1552897,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":63890,"kind":"person","name":"Simonian Nancy A","position":1,"cik":"0001359574","reported_name":"Simonian Nancy A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-02T16:59:57.000Z","date":"2024-03-31","kind":"exercise","planned":false,"acquired":true,"shares":6000,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock received upon vesting of a restricted stock unit award."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of common stock received upon vesting of a restricted stock unit award."}],"balance_after":106144,"source":{"system":"sec-edgar","filing":"0000950170-24-040308","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1359574/000095017024040308/ownership.xml","form_type":"4"}},{"id":1709974,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":63890,"kind":"person","name":"Simonian Nancy A","position":1,"cik":"0001359574","reported_name":"Simonian Nancy A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2023-12-15T18:46:58.000Z","date":"2023-12-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2044,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit granted after March 12, 2023 that was unvested as of immediately prior to the Effective Time (each, a \"Post-Signing Company RSU\") was cancelled and converted into the right to receive a Parent cash-based award subject to service-based vesting requirements with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Post-Signing Company RSU."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the disposition of shares of common stock, par value $0.001 per share (\"Common Stock\"), of Seagen Inc. (\"Issuer\"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the \"Merger Agreement\"), by and among the Issuer, Pfizer Inc. (\"Parent\") and Aris Merger Sub, Inc. (\"Merger Sub\"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit granted after March 12, 2023 that was unvested as of immediately prior to the Effective Time (each, a \"Post-Signing Company RSU\") was cancelled and converted into the right to receive a Parent cash-based award subject to service-based vesting requirements with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Post-Signing Company RSU."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit granted after March 12, 2023 that was unvested as of immediately prior to the Effective Time (each, a \"Post-Signing Company RSU\") was cancelled and converted into the right to receive a Parent cash-based award subject to service-based vesting requirements with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Post-Signing Company RSU."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit granted after March 12, 2023 that was unvested as of immediately prior to the Effective Time (each, a \"Post-Signing Company RSU\") was cancelled and converted into the right to receive a Parent cash-based award subject to service-based vesting requirements with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Post-Signing Company RSU."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":2044},"source":{"system":"sec-edgar","filing":"0000950170-23-070884","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000095017023070884/ownership.xml","form_type":"4"}},{"id":1709973,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":63890,"kind":"person","name":"Simonian Nancy A","position":1,"cik":"0001359574","reported_name":"Simonian Nancy A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2023-12-15T18:46:58.000Z","date":"2023-12-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3676,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the disposition of shares of common stock, par value $0.001 per share (\"Common Stock\"), of Seagen Inc. (\"Issuer\"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the \"Merger Agreement\"), by and among the Issuer, Pfizer Inc. (\"Parent\") and Aris Merger Sub, Inc. (\"Merger Sub\"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option."}],"balance_after":0,"derivative":{"exercise_price":135.63,"expiration_date":"2032-05-13","underlying":"Common stock","underlying_shares":3676},"source":{"system":"sec-edgar","filing":"0000950170-23-070884","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000095017023070884/ownership.xml","form_type":"4"}},{"id":1709972,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":63890,"kind":"person","name":"Simonian Nancy A","position":1,"cik":"0001359574","reported_name":"Simonian Nancy A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2023-12-15T18:46:58.000Z","date":"2023-12-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3462,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the disposition of shares of common stock, par value $0.001 per share (\"Common Stock\"), of Seagen Inc. (\"Issuer\"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the \"Merger Agreement\"), by and among the Issuer, Pfizer Inc. (\"Parent\") and Aris Merger Sub, Inc. (\"Merger Sub\"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option."}],"balance_after":0,"derivative":{"exercise_price":147.5,"expiration_date":"2031-05-14","underlying":"Common stock","underlying_shares":3462},"source":{"system":"sec-edgar","filing":"0000950170-23-070884","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000095017023070884/ownership.xml","form_type":"4"}},{"id":1709971,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":63890,"kind":"person","name":"Simonian Nancy A","position":1,"cik":"0001359574","reported_name":"Simonian Nancy A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2023-12-15T18:46:58.000Z","date":"2023-12-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3171,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the disposition of shares of common stock, par value $0.001 per share (\"Common Stock\"), of Seagen Inc. (\"Issuer\"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the \"Merger Agreement\"), by and among the Issuer, Pfizer Inc. (\"Parent\") and Aris Merger Sub, Inc. (\"Merger Sub\"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option."}],"balance_after":0,"derivative":{"exercise_price":160.33,"expiration_date":"2030-05-15","underlying":"Common stock","underlying_shares":3171},"source":{"system":"sec-edgar","filing":"0000950170-23-070884","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000095017023070884/ownership.xml","form_type":"4"}},{"id":1709970,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":63890,"kind":"person","name":"Simonian Nancy A","position":1,"cik":"0001359574","reported_name":"Simonian Nancy A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2023-12-15T18:46:58.000Z","date":"2023-12-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7038,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the disposition of shares of common stock, par value $0.001 per share (\"Common Stock\"), of Seagen Inc. (\"Issuer\"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the \"Merger Agreement\"), by and among the Issuer, Pfizer Inc. (\"Parent\") and Aris Merger Sub, Inc. (\"Merger Sub\"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option."}],"balance_after":0,"derivative":{"exercise_price":64.38,"expiration_date":"2029-05-20","underlying":"Common stock","underlying_shares":7038},"source":{"system":"sec-edgar","filing":"0000950170-23-070884","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000095017023070884/ownership.xml","form_type":"4"}},{"id":1709969,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":63890,"kind":"person","name":"Simonian Nancy A","position":1,"cik":"0001359574","reported_name":"Simonian Nancy A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2023-12-15T18:46:58.000Z","date":"2023-12-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":9260,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the disposition of shares of common stock, par value $0.001 per share (\"Common Stock\"), of Seagen Inc. (\"Issuer\"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the \"Merger Agreement\"), by and among the Issuer, Pfizer Inc. (\"Parent\") and Aris Merger Sub, Inc. (\"Merger Sub\"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option."}],"balance_after":0,"derivative":{"exercise_price":56.77,"expiration_date":"2028-05-18","underlying":"Common stock","underlying_shares":9260},"source":{"system":"sec-edgar","filing":"0000950170-23-070884","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000095017023070884/ownership.xml","form_type":"4"}},{"id":1709968,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":63890,"kind":"person","name":"Simonian Nancy A","position":1,"cik":"0001359574","reported_name":"Simonian Nancy A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2023-12-15T18:46:58.000Z","date":"2023-12-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":9260,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the disposition of shares of common stock, par value $0.001 per share (\"Common Stock\"), of Seagen Inc. (\"Issuer\"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the \"Merger Agreement\"), by and among the Issuer, Pfizer Inc. (\"Parent\") and Aris Merger Sub, Inc. (\"Merger Sub\"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option."}],"balance_after":0,"derivative":{"exercise_price":66.6,"expiration_date":"2027-05-19","underlying":"Common stock","underlying_shares":9260},"source":{"system":"sec-edgar","filing":"0000950170-23-070884","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000095017023070884/ownership.xml","form_type":"4"}},{"id":1709967,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":63890,"kind":"person","name":"Simonian Nancy A","position":1,"cik":"0001359574","reported_name":"Simonian Nancy A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2023-12-15T18:46:58.000Z","date":"2023-12-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":9260,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the disposition of shares of common stock, par value $0.001 per share (\"Common Stock\"), of Seagen Inc. (\"Issuer\"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the \"Merger Agreement\"), by and among the Issuer, Pfizer Inc. (\"Parent\") and Aris Merger Sub, Inc. (\"Merger Sub\"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option."}],"balance_after":0,"derivative":{"exercise_price":38.82,"expiration_date":"2026-05-20","underlying":"Common stock","underlying_shares":9260},"source":{"system":"sec-edgar","filing":"0000950170-23-070884","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000095017023070884/ownership.xml","form_type":"4"}},{"id":1709966,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":63890,"kind":"person","name":"Simonian Nancy A","position":1,"cik":"0001359574","reported_name":"Simonian Nancy A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2023-12-15T18:46:58.000Z","date":"2023-12-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":9260,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the disposition of shares of common stock, par value $0.001 per share (\"Common Stock\"), of Seagen Inc. (\"Issuer\"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the \"Merger Agreement\"), by and among the Issuer, Pfizer Inc. (\"Parent\") and Aris Merger Sub, Inc. (\"Merger Sub\"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option."}],"balance_after":0,"derivative":{"exercise_price":39.94,"expiration_date":"2025-05-15","underlying":"Common stock","underlying_shares":9260},"source":{"system":"sec-edgar","filing":"0000950170-23-070884","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000095017023070884/ownership.xml","form_type":"4"}},{"id":1709965,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":63890,"kind":"person","name":"Simonian Nancy A","position":1,"cik":"0001359574","reported_name":"Simonian Nancy A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2023-12-15T18:46:58.000Z","date":"2023-12-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":8750,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the disposition of shares of common stock, par value $0.001 per share (\"Common Stock\"), of Seagen Inc. (\"Issuer\"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the \"Merger Agreement\"), by and among the Issuer, Pfizer Inc. (\"Parent\") and Aris Merger Sub, Inc. (\"Merger Sub\"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option."}],"balance_after":0,"derivative":{"exercise_price":34.25,"expiration_date":"2024-05-16","underlying":"Common stock","underlying_shares":8750},"source":{"system":"sec-edgar","filing":"0000950170-23-070884","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000095017023070884/ownership.xml","form_type":"4"}},{"id":1709964,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":63890,"kind":"person","name":"Simonian Nancy A","position":1,"cik":"0001359574","reported_name":"Simonian Nancy A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-15T18:46:58.000Z","date":"2023-12-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":62753,"price":229,"value":14370437.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the disposition of shares of common stock, par value $0.001 per share (\"Common Stock\"), of Seagen Inc. (\"Issuer\"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the \"Merger Agreement\"), by and among the Issuer, Pfizer Inc. (\"Parent\") and Aris Merger Sub, Inc. (\"Merger Sub\"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the \"Merger\")."},{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the disposition of shares of common stock, par value $0.001 per share (\"Common Stock\"), of Seagen Inc. (\"Issuer\"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the \"Merger Agreement\"), by and among the Issuer, Pfizer Inc. (\"Parent\") and Aris Merger Sub, Inc. (\"Merger Sub\"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the disposition of shares of common stock, par value $0.001 per share (\"Common Stock\"), of Seagen Inc. (\"Issuer\"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the \"Merger Agreement\"), by and among the Issuer, Pfizer Inc. (\"Parent\") and Aris Merger Sub, Inc. (\"Merger Sub\"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each issued and outstanding share of Common Stock (other than certain excluded shares described in the Merger Agreement) was cancelled and converted automatically into the right to receive cash in an amount equal to $229.00 per share of Common Stock (the \"Merger Consideration\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-23-070884","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000095017023070884/ownership.xml","form_type":"4"}},{"id":1721262,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":63890,"kind":"person","name":"Simonian Nancy A","position":1,"cik":"0001359574","reported_name":"Simonian Nancy A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-12-05T17:23:22.000Z","date":"2023-12-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":30399,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The option was canceled by mutual agreement of the reporting person and the issuer pursuant to the terms of the Retirement and Transition Agreement, dated September 28, 2023, by and between the reporting person and the issuer, a copy of which was filed on November 14, 2023 as Exhibit 10.1 to the issuer's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option vested as to 25% of the shares on February 28, 2022, with the remainder vesting in equal monthly installments thereafter through February 28, 2025."}],"balance_after":0,"derivative":{"exercise_price":114.1,"expiration_date":"2031-02-16","underlying":"Common Stock","underlying_shares":30399},"source":{"system":"sec-edgar","filing":"0000950170-23-068283","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1359574/000095017023068283/ownership.xml","form_type":"4"}},{"id":1721261,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":63890,"kind":"person","name":"Simonian Nancy A","position":1,"cik":"0001359574","reported_name":"Simonian Nancy A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-12-05T17:23:22.000Z","date":"2023-12-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":29399,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The option was canceled by mutual agreement of the reporting person and the issuer pursuant to the terms of the Retirement and Transition Agreement, dated September 28, 2023, by and between the reporting person and the issuer, a copy of which was filed on November 14, 2023 as Exhibit 10.1 to the issuer's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option vested as to 25% of the shares on February 28, 2021, with the remainder vesting in equal monthly installments thereafter through February 28, 2024."}],"balance_after":0,"derivative":{"exercise_price":75.4,"expiration_date":"2030-02-12","underlying":"Common Stock","underlying_shares":29399},"source":{"system":"sec-edgar","filing":"0000950170-23-068283","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1359574/000095017023068283/ownership.xml","form_type":"4"}},{"id":1721260,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":63890,"kind":"person","name":"Simonian Nancy A","position":1,"cik":"0001359574","reported_name":"Simonian Nancy A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-12-05T17:23:22.000Z","date":"2023-12-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":28001,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The option was canceled by mutual agreement of the reporting person and the issuer pursuant to the terms of the Retirement and Transition Agreement, dated September 28, 2023, by and between the reporting person and the issuer, a copy of which was filed on November 14, 2023 as Exhibit 10.1 to the issuer's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Fully vested."}],"balance_after":0,"derivative":{"exercise_price":100.9,"expiration_date":"2028-02-15","underlying":"Common Stock","underlying_shares":28001},"source":{"system":"sec-edgar","filing":"0000950170-23-068283","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1359574/000095017023068283/ownership.xml","form_type":"4"}},{"id":1721259,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":63890,"kind":"person","name":"Simonian Nancy A","position":1,"cik":"0001359574","reported_name":"Simonian Nancy A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-12-05T17:23:22.000Z","date":"2023-12-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":17499,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The option was canceled by mutual agreement of the reporting person and the issuer pursuant to the terms of the Retirement and Transition Agreement, dated September 28, 2023, by and between the reporting person and the issuer, a copy of which was filed on November 14, 2023 as Exhibit 10.1 to the issuer's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Fully vested."}],"balance_after":0,"derivative":{"exercise_price":109,"expiration_date":"2027-02-09","underlying":"Common Stock","underlying_shares":17499},"source":{"system":"sec-edgar","filing":"0000950170-23-068283","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1359574/000095017023068283/ownership.xml","form_type":"4"}},{"id":1721258,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":63890,"kind":"person","name":"Simonian Nancy A","position":1,"cik":"0001359574","reported_name":"Simonian Nancy A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-12-05T17:23:22.000Z","date":"2023-12-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The option was canceled by mutual agreement of the reporting person and the issuer pursuant to the terms of the Retirement and Transition Agreement, dated September 28, 2023, by and between the reporting person and the issuer, a copy of which was filed on November 14, 2023 as Exhibit 10.1 to the issuer's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Fully vested."}],"balance_after":0,"derivative":{"exercise_price":121.7,"expiration_date":"2026-09-15","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0000950170-23-068283","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1359574/000095017023068283/ownership.xml","form_type":"4"}},{"id":1751108,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":63890,"kind":"person","name":"Simonian Nancy A","position":1,"cik":"0001359574","reported_name":"Simonian Nancy A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Restricted Stock Units","published_at":"2023-11-02T16:54:12.000Z","date":"2023-10-31","kind":"exercise","planned":false,"acquired":false,"shares":40125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Represents a restricted stock unit award granted on October 6, 2022. These restricted stock units vested as to one half (50%) of the shares on\nOctober 31, 2023, and are scheduled to vest as to one half (50%) of the shares on October 31, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Represents a restricted stock unit award granted on October 6, 2022. These restricted stock units vested as to one half (50%) of the shares on\nOctober 31, 2023, and are scheduled to vest as to one half (50%) of the shares on October 31, 2024."}],"balance_after":40125,"derivative":{"underlying":"Common Stock","underlying_shares":40125},"source":{"system":"sec-edgar","filing":"0001209191-23-054174","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1359574/000120919123054174/doc4.xml","form_type":"4"}},{"id":1751107,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":63890,"kind":"person","name":"Simonian Nancy A","position":1,"cik":"0001359574","reported_name":"Simonian Nancy A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2023-11-02T16:54:12.000Z","date":"2023-11-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":13401,"price":2.22,"value":29750.22,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares used to cover tax withholding on a restricted stock unit release."}],"balance_after":100144,"source":{"system":"sec-edgar","filing":"0001209191-23-054174","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1359574/000120919123054174/doc4.xml","form_type":"4"}},{"id":1751106,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":63890,"kind":"person","name":"Simonian Nancy A","position":1,"cik":"0001359574","reported_name":"Simonian Nancy A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2023-11-02T16:54:12.000Z","date":"2023-10-31","kind":"exercise","planned":false,"acquired":true,"shares":40125,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock received upon vesting of a restricted stock unit award."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of common stock received upon vesting of a restricted stock unit award."}],"balance_after":113545,"source":{"system":"sec-edgar","filing":"0001209191-23-054174","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1359574/000120919123054174/doc4.xml","form_type":"4"}},{"id":1870675,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":63890,"kind":"person","name":"Simonian Nancy A","position":1,"cik":"0001359574","reported_name":"Simonian Nancy A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-02T18:20:20.000Z","date":"2023-05-31","kind":"grant","planned":false,"acquired":true,"shares":2044,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These securities are restricted stock units and will be settled in common stock upon vesting."},{"field":"shares","element":"transactionShares","label":"F2","text":"These restricted stock units shall vest in full on May 31, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting."}],"balance_after":64797,"source":{"system":"sec-edgar","filing":"0001203311-23-000059","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000120331123000059/edgardoc.xml","form_type":"4"}},{"id":1927182,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":63890,"kind":"person","name":"Simonian Nancy A","position":1,"cik":"0001359574","reported_name":"Simonian Nancy A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Restricted Stock Units","published_at":"2023-04-04T18:54:18.000Z","date":"2023-03-31","kind":"exercise","planned":false,"acquired":false,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Represents a restricted stock unit award granted on February 15, 2022. These restricted stock units vest in four equal annual installments commencing on March 31, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Represents a restricted stock unit award granted on February 15, 2022. These restricted stock units vest in four equal annual installments commencing on March 31, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On September 16, 2022, the issuer effected a 1-for-10 reverse stock split of its common stock (the \"Reverse Stock Split\"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split."}],"balance_after":18000,"derivative":{"underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001209191-23-022969","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1359574/000120919123022969/doc4.xml","form_type":"4"}},{"id":1927181,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":63890,"kind":"person","name":"Simonian Nancy A","position":1,"cik":"0001359574","reported_name":"Simonian Nancy A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2023-04-04T18:54:18.000Z","date":"2023-04-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":1852,"price":2.58,"value":4778.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents shares used to cover tax withholding on a restricted stock unit release."}],"balance_after":73420,"source":{"system":"sec-edgar","filing":"0001209191-23-022969","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1359574/000120919123022969/doc4.xml","form_type":"4"}},{"id":1927180,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":63890,"kind":"person","name":"Simonian Nancy A","position":1,"cik":"0001359574","reported_name":"Simonian Nancy A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2023-04-04T18:54:18.000Z","date":"2023-03-31","kind":"exercise","planned":false,"acquired":true,"shares":6000,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock received upon vesting of a restricted stock unit award."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of common stock received upon vesting of a restricted stock unit award."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On September 16, 2022, the issuer effected a 1-for-10 reverse stock split of its common stock (the \"Reverse Stock Split\"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split."}],"balance_after":75272,"source":{"system":"sec-edgar","filing":"0001209191-23-022969","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1359574/000120919123022969/doc4.xml","form_type":"4"}},{"id":2003009,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":63890,"kind":"person","name":"Simonian Nancy A","position":1,"cik":"0001359574","reported_name":"Simonian Nancy A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Restricted Stock Units","published_at":"2023-02-21T16:17:44.000Z","date":"2023-02-16","kind":"grant","acquired":true,"shares":118700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents the contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These RSUs will vest as to one third (1/3rd) of the shares underlying the award on March 31, 2024 and as to an additional one third (1/3rd) of such shares at the end of each successive year thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"These RSUs will vest as to one third (1/3rd) of the shares underlying the award on March 31, 2024 and as to an additional one third (1/3rd) of such shares at the end of each successive year thereafter."}],"balance_after":118700,"derivative":{"underlying":"Common Stock","underlying_shares":118700},"source":{"system":"sec-edgar","filing":"0001209191-23-011151","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1359574/000120919123011151/doc4.xml","form_type":"4"}},{"id":2086860,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":63890,"kind":"person","name":"Simonian Nancy A","position":1,"cik":"0001359574","reported_name":"Simonian Nancy A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2022-12-14T17:49:08.000Z","date":"2022-12-12","kind":"exercise","acquired":false,"shares":8750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Options were fully vested on 5/16/14."}],"balance_after":0,"derivative":{"exercise_price":36.7,"expiration_date":"2023-05-17","underlying":"Common Stock","underlying_shares":8750},"source":{"system":"sec-edgar","filing":"0001203311-22-000065","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000120331122000065/edgardoc.xml","form_type":"4"}},{"id":2086859,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":63890,"kind":"person","name":"Simonian Nancy A","position":1,"cik":"0001359574","reported_name":"Simonian Nancy A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-14T17:49:08.000Z","date":"2022-12-12","kind":"exercise","acquired":true,"shares":8750,"price":36.7,"value":321125.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting."}],"balance_after":62753,"source":{"system":"sec-edgar","filing":"0001203311-22-000065","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000120331122000065/edgardoc.xml","form_type":"4"}},{"id":2139055,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":63890,"kind":"person","name":"Simonian Nancy A","position":1,"cik":"0001359574","reported_name":"Simonian Nancy A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Restricted Stock Units","published_at":"2022-10-11T16:36:47.000Z","date":"2022-10-06","kind":"grant","acquired":true,"shares":80250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (\"RSU\") represents the contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These RSUs will vest as to one half (50%) of the shares on October 31, 2023, and as to one half (50%) of the shares on October 31, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"These RSUs will vest as to one half (50%) of the shares on October 31, 2023, and as to one half (50%) of the shares on October 31, 2024."}],"balance_after":80250,"derivative":{"underlying":"Common Stock","underlying_shares":80250},"source":{"system":"sec-edgar","filing":"0001209191-22-053315","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1359574/000120919122053315/doc4.xml","form_type":"4"}},{"id":2139054,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":63890,"kind":"person","name":"Simonian Nancy A","position":1,"cik":"0001359574","reported_name":"Simonian Nancy A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2022-10-11T16:36:47.000Z","date":"2022-10-06","kind":"grant","acquired":true,"shares":115000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option becomes exercisable as to one half (50%) of the shares on October 31, 2023, and as to one half (50%) of the shares on October 31, 2024."}],"balance_after":115000,"derivative":{"exercise_price":6.73,"expiration_date":"2032-10-05","underlying":"Common Stock","underlying_shares":115000},"source":{"system":"sec-edgar","filing":"0001209191-22-053315","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1359574/000120919122053315/doc4.xml","form_type":"4"}},{"id":2268738,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":63890,"kind":"person","name":"Simonian Nancy A","position":1,"cik":"0001359574","reported_name":"Simonian Nancy A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2022-05-17T19:28:15.000Z","date":"2022-05-13","kind":"grant","acquired":true,"shares":3676,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":3676,"derivative":{"exercise_price":135.63,"exercise_date":"2023-05-13","expiration_date":"2032-05-13","underlying":"Common Stock","underlying_shares":3676},"source":{"system":"sec-edgar","filing":"0000899243-22-018458","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000089924322018458/doc4.xml","form_type":"4"}},{"id":2268737,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":63890,"kind":"person","name":"Simonian Nancy A","position":1,"cik":"0001359574","reported_name":"Simonian Nancy A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-17T19:28:15.000Z","date":"2022-05-13","kind":"grant","acquired":true,"shares":1503,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These restricted stock units will be settled in common stock upon vesting."},{"field":"shares","element":"transactionShares","label":"F2","text":"These restricted stock units shall vest in full on May 13, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting."}],"balance_after":54003,"source":{"system":"sec-edgar","filing":"0000899243-22-018458","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000089924322018458/doc4.xml","form_type":"4"}},{"id":2307494,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":63890,"kind":"person","name":"Simonian Nancy A","position":1,"cik":"0001359574","reported_name":"Simonian Nancy A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2022-04-04T17:02:10.000Z","date":"2022-04-01","kind":"tax_withholding","acquired":false,"shares":58883,"price":1.12,"value":65948.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares used to cover tax withholding on a Restricted Stock Unit release."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 129,117 shares of common stock released from the Restricted Stock Unit award reported on a Form 4 dated February 14, 2019."}],"balance_after":692723,"source":{"system":"sec-edgar","filing":"0001209191-22-022499","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1359574/000120919122022499/doc4.xml","form_type":"4"}},{"id":2351115,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":63890,"kind":"person","name":"Simonian Nancy A","position":1,"cik":"0001359574","reported_name":"Simonian Nancy A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2022-03-04T17:09:34.000Z","date":"2022-03-02","kind":"exercise","acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Options vested at a rate of 25% on 3/19/13 and monthly thereafter until all the options were fully vested on 3/19/16."}],"balance_after":0,"derivative":{"exercise_price":20.04,"expiration_date":"2022-03-19","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000899243-22-009424","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000089924322009424/doc4.xml","form_type":"4"}},{"id":2351114,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":63890,"kind":"person","name":"Simonian Nancy A","position":1,"cik":"0001359574","reported_name":"Simonian Nancy A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-03-04T17:09:34.000Z","date":"2022-03-02","kind":"exercise","acquired":true,"shares":25000,"price":20.04,"value":501000.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting."}],"balance_after":52500,"source":{"system":"sec-edgar","filing":"0000899243-22-009424","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000089924322009424/doc4.xml","form_type":"4"}},{"id":2387792,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":63890,"kind":"person","name":"Simonian Nancy A","position":1,"cik":"0001359574","reported_name":"Simonian Nancy A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Restricted Stock Units","published_at":"2022-02-17T16:05:43.000Z","date":"2022-02-15","kind":"grant","acquired":true,"shares":400000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (\"RSU\") represents the contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These RSUs will vest in full on March 31, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"These RSUs will vest in full on March 31, 2025."}],"balance_after":400000,"derivative":{"underlying":"Common Stock","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0001209191-22-010702","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1359574/000120919122010702/doc4.xml","form_type":"4"}},{"id":2387791,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":63890,"kind":"person","name":"Simonian Nancy A","position":1,"cik":"0001359574","reported_name":"Simonian Nancy A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Restricted Stock Units","published_at":"2022-02-17T16:05:43.000Z","date":"2022-02-15","kind":"grant","acquired":true,"shares":240000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (\"RSU\") represents the contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These RSUs will vest in four equal annual installments commencing on March 31, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"These RSUs will vest in four equal annual installments commencing on March 31, 2023."}],"balance_after":240000,"derivative":{"underlying":"Common Stock","underlying_shares":240000},"source":{"system":"sec-edgar","filing":"0001209191-22-010702","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1359574/000120919122010702/doc4.xml","form_type":"4"}},{"id":2387790,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":63890,"kind":"person","name":"Simonian Nancy A","position":1,"cik":"0001359574","reported_name":"Simonian Nancy A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2022-02-17T16:05:43.000Z","date":"2022-02-15","kind":"grant","acquired":true,"shares":375000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option becomes exercisable as to one quarter (1/4th) of the shares on February 28, 2023, with the remainder vesting in monthly installments equal to one forty-eighth (1/48th) of the original number of shares at the end of each of the next thirty-six (36) months thereafter."}],"balance_after":375000,"derivative":{"exercise_price":1.59,"expiration_date":"2032-02-14","underlying":"Common Stock","underlying_shares":375000},"source":{"system":"sec-edgar","filing":"0001209191-22-010702","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1359574/000120919122010702/doc4.xml","form_type":"4"}},{"id":2708757,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":63890,"kind":"person","name":"Simonian Nancy A","position":1,"cik":"0001359574","reported_name":"Simonian Nancy A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2021-05-18T19:35:19.000Z","date":"2021-05-14","kind":"grant","acquired":true,"shares":3462,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":3462,"derivative":{"exercise_price":147.5,"exercise_date":"2022-05-14","expiration_date":"2031-05-14","underlying":"Common Stock","underlying_shares":3462},"source":{"system":"sec-edgar","filing":"0001203311-21-000036","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000120331121000036/edgardoc.xml","form_type":"4"}},{"id":2708756,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":63890,"kind":"person","name":"Simonian Nancy A","position":1,"cik":"0001359574","reported_name":"Simonian Nancy A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-18T19:35:19.000Z","date":"2021-05-14","kind":"grant","acquired":true,"shares":1402,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These restricted stock units will be settled in common stock upon vesting."},{"field":"date","element":"transactionDate","label":"F2","text":"These restricted stock units shall vest in full on May 14, 2022."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting."}],"balance_after":27500,"source":{"system":"sec-edgar","filing":"0001203311-21-000036","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000120331121000036/edgardoc.xml","form_type":"4"}},{"id":2845704,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":63890,"kind":"person","name":"Simonian Nancy A","position":1,"cik":"0001359574","reported_name":"Simonian Nancy A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2021-02-19T16:10:43.000Z","date":"2021-02-17","kind":"grant","acquired":true,"shares":304000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option becomes exercisable as to one quarter (1/4th) of the shares on February 28, 2022, with the remainder vesting in monthly installments equal to one forty-eighth (1/48th) of the original number of shares at the end of each of the next thirty-six (36) months thereafter."}],"balance_after":304000,"derivative":{"exercise_price":11.41,"expiration_date":"2031-02-16","underlying":"Common Stock","underlying_shares":304000},"source":{"system":"sec-edgar","filing":"0001209191-21-012331","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1359574/000120919121012331/doc4.xml","form_type":"4"}},{"id":2935907,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":63890,"kind":"person","name":"Simonian Nancy A","position":1,"cik":"0001359574","reported_name":"Simonian Nancy A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2020-12-21T16:58:58.000Z","date":"2020-12-18","kind":"exercise","acquired":false,"shares":4988,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option to purchase 285,000 shares became exercisable as to 25% of the shares underlying the award on February 28, 2019, with the remainder vesting in equal monthly installments of 2.0833% of the shares underlying the award at the end of each successive month thereafter."}],"balance_after":280012,"derivative":{"exercise_price":10.09,"expiration_date":"2028-02-15","underlying":"Common Stock","underlying_shares":4988},"source":{"system":"sec-edgar","filing":"0001209191-20-064667","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1359574/000120919120064667/doc4.xml","form_type":"4"}},{"id":2935906,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":63890,"kind":"person","name":"Simonian Nancy A","position":1,"cik":"0001359574","reported_name":"Simonian Nancy A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2020-12-21T16:58:58.000Z","date":"2020-12-18","kind":"exercise","acquired":false,"shares":14168,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option is fully vested."}],"balance_after":79165,"derivative":{"exercise_price":8.51,"expiration_date":"2026-03-31","underlying":"Common Stock","underlying_shares":14168},"source":{"system":"sec-edgar","filing":"0001209191-20-064667","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1359574/000120919120064667/doc4.xml","form_type":"4"}},{"id":2935905,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":63890,"kind":"person","name":"Simonian Nancy A","position":1,"cik":"0001359574","reported_name":"Simonian Nancy A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2020-12-21T16:58:58.000Z","date":"2020-12-18","kind":"exercise","acquired":false,"shares":10761,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option is fully vested."}],"balance_after":21524,"derivative":{"exercise_price":3.04,"expiration_date":"2025-06-08","underlying":"Common Stock","underlying_shares":10761},"source":{"system":"sec-edgar","filing":"0001209191-20-064667","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1359574/000120919120064667/doc4.xml","form_type":"4"}},{"id":2935904,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":63890,"kind":"person","name":"Simonian Nancy A","position":1,"cik":"0001359574","reported_name":"Simonian Nancy A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-12-21T16:58:58.000Z","date":"2020-12-18","kind":"exercise","acquired":true,"shares":4988,"price":10.09,"value":50328.92,"ownership":{"direct":true},"balance_after":563606,"source":{"system":"sec-edgar","filing":"0001209191-20-064667","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1359574/000120919120064667/doc4.xml","form_type":"4"}},{"id":2935903,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":63890,"kind":"person","name":"Simonian Nancy A","position":1,"cik":"0001359574","reported_name":"Simonian Nancy A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-12-21T16:58:58.000Z","date":"2020-12-18","kind":"exercise","acquired":true,"shares":14168,"price":8.51,"value":120569.68,"ownership":{"direct":true},"balance_after":558618,"source":{"system":"sec-edgar","filing":"0001209191-20-064667","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1359574/000120919120064667/doc4.xml","form_type":"4"}},{"id":2935902,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":63890,"kind":"person","name":"Simonian Nancy A","position":1,"cik":"0001359574","reported_name":"Simonian Nancy A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-12-21T16:58:58.000Z","date":"2020-12-18","kind":"exercise","acquired":true,"shares":10761,"price":3.04,"value":32713.44,"ownership":{"direct":true},"balance_after":544450,"source":{"system":"sec-edgar","filing":"0001209191-20-064667","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1359574/000120919120064667/doc4.xml","form_type":"4"}},{"id":3105603,"issuer":{"id":108468,"kind":"organization","name":"Evelo Biosciences, Inc.","symbol":"EVLO"},"owners":[{"id":63890,"kind":"person","name":"Simonian Nancy A","position":1,"cik":"0001359574","reported_name":"Simonian Nancy A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-18T17:14:17.000Z","date":"2020-06-17","kind":"grant","acquired":true,"shares":15690,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests on the earlier of June 17, 2021 or the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant, in either case subject to the Reporting Person continuing in service on the Issuer's board of directors as a non-employee director through such vesting date."}],"balance_after":15690,"derivative":{"exercise_price":3.59,"expiration_date":"2030-06-17","underlying":"Common Stock","underlying_shares":15690},"source":{"system":"sec-edgar","filing":"0001694665-20-000058","document":"wf-form4_159251484038936.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1694665/000169466520000058/wf-form4_159251484038936.xml","form_type":"4"}},{"id":3143490,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":63890,"kind":"person","name":"Simonian Nancy A","position":1,"cik":"0001359574","reported_name":"Simonian Nancy A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2020-05-19T19:11:15.000Z","date":"2020-05-15","kind":"grant","acquired":true,"shares":3171,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":3171,"derivative":{"exercise_price":160.33,"exercise_date":"2021-05-15","expiration_date":"2030-05-15","underlying":"Common Stock","underlying_shares":3171},"source":{"system":"sec-edgar","filing":"0001203311-20-000051","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000120331120000051/edgardoc.xml","form_type":"4"}},{"id":3143489,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":63890,"kind":"person","name":"Simonian Nancy A","position":1,"cik":"0001359574","reported_name":"Simonian Nancy A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-05-19T19:11:15.000Z","date":"2020-05-15","kind":"grant","acquired":true,"shares":1335,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These restricted stock units will be settled in common stock upon vesting."},{"field":"date","element":"transactionDate","label":"F2","text":"These restricted stock units shall vest in full on May 15, 2021."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting."}],"balance_after":26098,"source":{"system":"sec-edgar","filing":"0001203311-20-000051","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000120331120000051/edgardoc.xml","form_type":"4"}},{"id":3270038,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":63890,"kind":"person","name":"Simonian Nancy A","position":1,"cik":"0001359574","reported_name":"Simonian Nancy A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2020-02-14T16:04:40.000Z","date":"2020-02-13","kind":"grant","acquired":true,"shares":294000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option becomes exercisable as to 25% of the shares on February 28, 2021, with the remainder vesting in equal monthly installments of 2.0833% of the shares underlying the award at the end of each successive month thereafter."}],"balance_after":294000,"derivative":{"exercise_price":7.54,"expiration_date":"2030-02-12","underlying":"Common Stock","underlying_shares":294000},"source":{"system":"sec-edgar","filing":"0001209191-20-009591","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1359574/000120919120009591/doc4.xml","form_type":"4"}},{"id":3332281,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":63890,"kind":"person","name":"Simonian Nancy A","position":1,"cik":"0001359574","reported_name":"Simonian Nancy A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2019-12-23T16:54:10.000Z","date":"2019-12-23","kind":"exercise","acquired":false,"shares":8210,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option is fully vested."}],"balance_after":1018123,"derivative":{"exercise_price":3.04,"expiration_date":"2025-06-08","underlying":"Common Stock","underlying_shares":8210},"source":{"system":"sec-edgar","filing":"0001209191-19-061818","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1359574/000120919119061818/doc4.xml","form_type":"4"}},{"id":3332280,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":63890,"kind":"person","name":"Simonian Nancy A","position":1,"cik":"0001359574","reported_name":"Simonian Nancy A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2019-12-23T16:54:10.000Z","date":"2019-12-23","kind":"exercise","acquired":false,"shares":10762,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on June 9, 2015 and vests upon the achievement of performance-based criteria, and in any event will vest in full on June 9, 2021, subject to continued service."}],"balance_after":1026333,"derivative":{"exercise_price":3.04,"expiration_date":"2025-06-08","underlying":"Common Stock","underlying_shares":10762},"source":{"system":"sec-edgar","filing":"0001209191-19-061818","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1359574/000120919119061818/doc4.xml","form_type":"4"}},{"id":3332279,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":63890,"kind":"person","name":"Simonian Nancy A","position":1,"cik":"0001359574","reported_name":"Simonian Nancy A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2019-12-23T16:54:10.000Z","date":"2019-12-23","kind":"exercise","acquired":false,"shares":33429,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option is fully vested."}],"balance_after":1037095,"derivative":{"exercise_price":3.04,"expiration_date":"2024-02-04","underlying":"Common Stock","underlying_shares":33429},"source":{"system":"sec-edgar","filing":"0001209191-19-061818","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1359574/000120919119061818/doc4.xml","form_type":"4"}},{"id":3332278,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":63890,"kind":"person","name":"Simonian Nancy A","position":1,"cik":"0001359574","reported_name":"Simonian Nancy A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-12-23T16:54:10.000Z","date":"2019-12-23","kind":"exercise","acquired":true,"shares":52401,"price":3.04,"value":159299.04,"ownership":{"direct":true},"balance_after":533689,"source":{"system":"sec-edgar","filing":"0001209191-19-061818","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1359574/000120919119061818/doc4.xml","form_type":"4"}},{"id":3491464,"issuer":{"id":108468,"kind":"organization","name":"Evelo Biosciences, Inc.","symbol":"EVLO"},"owners":[{"id":63890,"kind":"person","name":"Simonian Nancy A","position":1,"cik":"0001359574","reported_name":"Simonian Nancy A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-13T08:28:12.000Z","date":"2019-06-12","kind":"grant","acquired":true,"shares":15690,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option vests on the earlier of June 12, 2020 or the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant, in either case subject to the Reporting Person continuing in service on the Issuer's board of directors as a non-employee director through each such vesting date."}],"balance_after":15690,"derivative":{"exercise_price":7.07,"expiration_date":"2029-06-12","underlying":"Common Stock","underlying_shares":15690},"source":{"system":"sec-edgar","filing":"0001694665-19-000041","document":"wf-form4_156042887728247.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1694665/000169466519000041/wf-form4_156042887728247.xml","form_type":"4"}},{"id":3515698,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":63890,"kind":"person","name":"Simonian Nancy A","position":1,"cik":"0001359574","reported_name":"Simonian Nancy A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2019-05-22T21:44:01.000Z","date":"2019-05-20","kind":"grant","acquired":true,"shares":7038,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These options shall vest in full on May 20, 2020."}],"balance_after":7038,"derivative":{"exercise_price":64.38,"expiration_date":"2029-05-20","underlying":"Common Stock","underlying_shares":7038},"source":{"system":"sec-edgar","filing":"0000899243-19-014440","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000089924319014440/doc4.xml","form_type":"4"}},{"id":3515697,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":63890,"kind":"person","name":"Simonian Nancy A","position":1,"cik":"0001359574","reported_name":"Simonian Nancy A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-05-22T21:44:01.000Z","date":"2019-05-20","kind":"grant","acquired":true,"shares":2963,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These restricted stock units will be settled in common stock upon vesting."},{"field":"date","element":"transactionDate","label":"F2","text":"These restricted stock units shall vest in full on May 20, 2020."}],"balance_after":24763,"source":{"system":"sec-edgar","filing":"0000899243-19-014440","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000089924319014440/doc4.xml","form_type":"4"}},{"id":3656080,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":63890,"kind":"person","name":"Simonian Nancy A","position":1,"cik":"0001359574","reported_name":"Simonian Nancy A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2019-02-14T17:19:19.000Z","date":"2019-02-12","kind":"grant","acquired":true,"shares":285000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option becomes exercisable as to 25% of the shares underlying the award on February 29, 2020, with the remainder vesting in equal monthly installments of 2.0833% of the shares underlying the award at the end of each successive month thereafter."}],"balance_after":285000,"derivative":{"exercise_price":6.71,"expiration_date":"2029-02-11","underlying":"Common Stock","underlying_shares":285000},"source":{"system":"sec-edgar","filing":"0001209191-19-010287","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1359574/000120919119010287/doc4.xml","form_type":"4"}},{"id":3656079,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":63890,"kind":"person","name":"Simonian Nancy A","position":1,"cik":"0001359574","reported_name":"Simonian Nancy A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-02-14T17:19:19.000Z","date":"2019-02-12","kind":"grant","acquired":true,"shares":188000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person was granted restricted stock units, with each unit representing the right to receive one share of the issuer's common stock.  These restricted stock units will vest in full on March 31, 2022."}],"balance_after":669288,"source":{"system":"sec-edgar","filing":"0001209191-19-010287","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1359574/000120919119010287/doc4.xml","form_type":"4"}},{"id":3745601,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":63890,"kind":"person","name":"Simonian Nancy A","position":1,"cik":"0001359574","reported_name":"Simonian Nancy A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2018-12-03T16:06:52.000Z","date":"2018-11-29","kind":"exercise","acquired":true,"shares":12084,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option is fully vested."}],"balance_after":785523,"derivative":{"exercise_price":3.04,"expiration_date":"2024-10-21","underlying":"Common Stock","underlying_shares":12084},"source":{"system":"sec-edgar","filing":"0001179110-18-013361","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1359574/000117911018013361/edgar.xml","form_type":"4"}},{"id":3745600,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":63890,"kind":"person","name":"Simonian Nancy A","position":1,"cik":"0001359574","reported_name":"Simonian Nancy A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2018-12-03T16:06:52.000Z","date":"2018-11-29","kind":"exercise","acquired":true,"shares":75050,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option is fully vested."}],"balance_after":797607,"derivative":{"exercise_price":1.01,"expiration_date":"2023-05-21","underlying":"Common Stock","underlying_shares":75050},"source":{"system":"sec-edgar","filing":"0001179110-18-013361","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1359574/000117911018013361/edgar.xml","form_type":"4"}},{"id":3745599,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":63890,"kind":"person","name":"Simonian Nancy A","position":1,"cik":"0001359574","reported_name":"Simonian Nancy A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2018-12-03T16:06:52.000Z","date":"2018-11-29","kind":"exercise","acquired":true,"shares":23454,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option is fully vested."}],"balance_after":872657,"derivative":{"exercise_price":1.01,"expiration_date":"2023-05-21","underlying":"Common Stock","underlying_shares":23454},"source":{"system":"sec-edgar","filing":"0001179110-18-013361","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1359574/000117911018013361/edgar.xml","form_type":"4"}},{"id":3745598,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":63890,"kind":"person","name":"Simonian Nancy A","position":1,"cik":"0001359574","reported_name":"Simonian Nancy A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-12-03T16:06:52.000Z","date":"2018-11-29","kind":"exercise","acquired":true,"shares":12084,"price":3.04,"value":36735.36,"ownership":{"direct":true},"balance_after":481288,"source":{"system":"sec-edgar","filing":"0001179110-18-013361","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1359574/000117911018013361/edgar.xml","form_type":"4"}},{"id":3745597,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":63890,"kind":"person","name":"Simonian Nancy A","position":1,"cik":"0001359574","reported_name":"Simonian Nancy A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-12-03T16:06:52.000Z","date":"2018-11-29","kind":"exercise","acquired":true,"shares":98504,"price":1.01,"value":99489.04,"ownership":{"direct":true},"balance_after":469204,"source":{"system":"sec-edgar","filing":"0001179110-18-013361","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1359574/000117911018013361/edgar.xml","form_type":"4"}},{"id":3922433,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":63890,"kind":"person","name":"Simonian Nancy A","position":1,"cik":"0001359574","reported_name":"Simonian Nancy A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2018-05-22T20:10:14.000Z","date":"2018-05-18","kind":"grant","acquired":true,"shares":9260,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option shall vest in full on May 18, 2019."}],"balance_after":9260,"derivative":{"exercise_price":56.77,"expiration_date":"2028-05-18","underlying":"Common Stock","underlying_shares":9260},"source":{"system":"sec-edgar","filing":"0001203311-18-000037","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000120331118000037/edgardoc.xml","form_type":"4"}},{"id":3922432,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":63890,"kind":"person","name":"Simonian Nancy A","position":1,"cik":"0001359574","reported_name":"Simonian Nancy A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-05-22T20:10:14.000Z","date":"2018-05-18","kind":"grant","acquired":true,"shares":3700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These shares represent restricted stock units and will be settled in common stock upon vesting."},{"field":"deemedExecutionDate","element":"deemedExecutionDate","label":"F2","text":"Restricted stock units shall vest in full on May 18, 2019."}],"balance_after":21800,"source":{"system":"sec-edgar","filing":"0001203311-18-000037","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000120331118000037/edgardoc.xml","form_type":"4"}},{"id":3939080,"issuer":{"id":108468,"kind":"organization","name":"Evelo Biosciences, Inc.","symbol":"EVLO"},"owners":[{"id":63890,"kind":"person","name":"Simonian Nancy A","position":1,"cik":"0001359574","reported_name":"Simonian Nancy A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2018-05-10T18:04:44.000Z","date":"2018-05-08","kind":"grant","acquired":true,"shares":31380,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in 36 equal monthly installments following the award grant date."}],"balance_after":31380,"derivative":{"exercise_price":16,"expiration_date":"2028-05-08","underlying":"Common Stock","underlying_shares":31380},"source":{"system":"sec-edgar","filing":"0000899243-18-012414","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1694665/000089924318012414/doc4.xml","form_type":"4"}},{"id":4043669,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":63890,"kind":"person","name":"Simonian Nancy A","position":1,"cik":"0001359574","reported_name":"Simonian Nancy A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2018-02-21T16:08:02.000Z","date":"2018-02-16","kind":"grant","acquired":true,"shares":285000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option becomes exercisable as to 25% of the shares underlying the award on February 28, 2019, with the remainder vesting in equal monthly installments of 2.0833% of the shares underlying the award at the end of each successive month thereafter."}],"balance_after":285000,"derivative":{"exercise_price":10.09,"expiration_date":"2028-02-15","underlying":"Common Stock","underlying_shares":285000},"source":{"system":"sec-edgar","filing":"0001179110-18-002463","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1359574/000117911018002463/edgar.xml","form_type":"4"}},{"id":4308589,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":63890,"kind":"person","name":"Simonian Nancy A","position":1,"cik":"0001359574","reported_name":"Simonian Nancy A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2017-05-23T19:22:15.000Z","date":"2017-05-19","kind":"grant","acquired":true,"shares":9260,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option shall vest in full on May 18, 2018."}],"balance_after":9260,"derivative":{"exercise_price":66.6,"expiration_date":"2027-05-18","underlying":"Common Stock","underlying_shares":9260},"source":{"system":"sec-edgar","filing":"0001203311-17-000024","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000120331117000024/edgardoc.xml","form_type":"4"}},{"id":4308588,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":63890,"kind":"person","name":"Simonian Nancy A","position":1,"cik":"0001359574","reported_name":"Simonian Nancy A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-05-23T19:22:15.000Z","date":"2017-05-19","kind":"grant","acquired":true,"shares":3700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These shares represent restricted stock units and will be settled in common stock upon vesting."},{"field":"date","element":"transactionDate","label":"F2","text":"Restricted stock units shall vest in full on May 18, 2018."}],"balance_after":18100,"source":{"system":"sec-edgar","filing":"0001203311-17-000024","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000120331117000024/edgardoc.xml","form_type":"4"}},{"id":4453491,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":63890,"kind":"person","name":"Simonian Nancy A","position":1,"cik":"0001359574","reported_name":"Simonian Nancy A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2017-02-13T17:17:06.000Z","date":"2017-02-10","kind":"grant","acquired":true,"shares":175000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option becomes exercisable as to 25% of the shares underlying the award on February 10, 2018, with the remainder vesting in equal monthly installments of 2.0833% of the shares underlying the award at the end of each successive month thereafter."}],"balance_after":175000,"derivative":{"exercise_price":10.9,"expiration_date":"2027-02-09","underlying":"Common Stock","underlying_shares":175000},"source":{"system":"sec-edgar","filing":"0001179110-17-002279","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1359574/000117911017002279/edgar.xml","form_type":"4"}},{"id":4599763,"issuer":{"id":85437,"kind":"organization","name":"Syros Pharmaceuticals, Inc.","symbol":"SYRS"},"owners":[{"id":63890,"kind":"person","name":"Simonian Nancy A","position":1,"cik":"0001359574","reported_name":"Simonian Nancy A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2016-09-19T06:59:51.000Z","date":"2016-09-16","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option becomes exercisable as to 25% of the shares underlying the award on the one year anniversary of the award, with the remainder vesting in equal monthly installments of 2.0833% of the shares underlying the award until the fourth anniversary of the date of the award, subject to Dr. Simonian's continued service through each applicable vesting date."}],"balance_after":75000,"derivative":{"exercise_price":12.17,"expiration_date":"2026-09-15","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001104659-16-145308","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1359574/000110465916145308/a4.xml","form_type":"4"}}]}